Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors

Oliva, Paola, Romagnoli, Romeo, Manfredini, Stefano, Brancale, Andrea, Ferla, Salvatore, Hamel, Ernest, Ronca, Roberto, Maccarinelli, Federica, Giacomini, Arianna, Rruga, Fatlum, Mariotto, Elena, Viola, Giampietro and Bortolozzi, Roberta 2020. Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. European Journal of Medicinal Chemistry 200 , 112448. 10.1016/j.ejmech.2020.112448 Item availability restricted.

PDF - Accepted Post-Print Version Restricted to Repository staff only until 12 May 2021 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB)

Abstract

A new class of inhibitors of tubulin polymerization based on the 2-amino-3-(3′,4′,5′-trimethoxybenzoyl)benzo[b]furan molecular scaffold was synthesized and evaluated for in vivo and in vitro biological activity. These derivatives were synthesized with different electron-releasing or electron-withdrawing substituents at one of the C-4 through C-7 positions. Methoxy substitution and location on the benzene part of the benzo[b]furan ring played an important role in affecting antiproliferative activity, with the greatest activity occurring with the methoxy group at the C-6 position, the least with the substituent at C-4. The same effect was also observed with ethoxy, methyl or bromine at the C-6 position of the benzo[b]furan skeleton, with the 6-ethoxy-2-amino-3-(3′,4′,5′-trimethoxybenzoyl)benzo[b]furan derivative 4f as the most promising compound of the series. This compound showed remarkable antiproliferative activity (IC50: 5 pM) against the Daoy medulloblastoma cell line, and 4f was nearly devoid of toxicity on healthy human lymphocytes and astrocytes. The potent antiproliferative activity of 4f was derived from its inhibition of tubulin polymerization by binding to the colchicine site. The compound was also examined for in vivo activity, showing higher potency at 15 mg/kg compared with the reference compound combretastatin A-4 phosphate at 30 mg/kg against a syngeneic murine mammary tumor.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	0223-5234
Date of First Compliant Deposit:	19 May 2020
Date of Acceptance:	9 May 2020
Last Modified:	30 Jun 2020 14:57
URI:	http://orca-mwe.cf.ac.uk/id/eprint/131812

Actions (repository staff only)

Edit Item